Search

Your search keyword '"Selina Chavda"' showing total 8 results
Start Over Author "Selina Chavda"
8 results on '"Selina Chavda"'

1. PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION

Author

Amrutha Sridhar, Selina Chavda, Hannah Hsu, Hanna Renshaw, Tatianna Fernandes, Catriona Maciter, Samir Asher, Neil Rabin, Jonathan Sive, Charalampia Kyriakou, Xenofon Papanikolaou, Ke Xu, Ashutosh Wechalekar, Shameem Mahmood, Annabel Mcmillan, Lydia Lee, Kwee Yong, Fatjon Dekaj, and Rakesh Popat

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Author

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, and Anjan Thakurta

Subjects
Ubiquitin-Protein Ligases, Immunology, Humans, Cell Biology, Hematology, RNA, Small Interfering, Multiple Myeloma, Lenalidomide, Biochemistry, Adaptor Proteins, Signal Transducing, Peptide Hydrolases
Abstract

The acquisition of a multidrug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the cereblon (CRBN) protein include widely used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase modulator drugs (CELMoDs), in clinical trials. CRBN genetic disruption causes resistance and poor outcomes with IMiDs. Here, we investigate alternative genomic associations of IMiD resistance, using large whole-genome sequencing patient datasets (n = 522 cases) at newly diagnosed, lenalidomide (LEN)-refractory and lenalidomide-then-pomalidomide (LEN-then-POM)-refractory timepoints. Selecting gene targets reproducibly identified by published CRISPR/shRNA IMiD resistance screens, we found little evidence of genetic disruption by mutation associated with IMiD resistance. However, we identified a chromosome region, 2q37, containing COP9 signalosome members COPS7B and COPS8, copy loss of which significantly enriches between newly diagnosed (incidence 5.5%), LEN-refractory (10.0%), and LEN-then-POM-refractory states (16.4%), and may adversely affect outcomes when clonal fraction is high. In a separate dataset (50 patients) with sequential samples taken throughout treatment, we identified acquisition of 2q37 loss in 16% cases with IMiD exposure, but none in cases without IMiD exposure. The COP9 signalosome is essential for maintenance of the CUL4-DDB1-CRBN E3 ubiquitin ligase. This region may represent a novel marker of IMiD resistance with clinical utility.

Published
2022
Full Text
View/download PDF

3. OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myeloma

Author

Ieuan Walker, Garima Khandelwal, Venetia D’Arcy, William Wilson, Evie Fitzsimons, Daria Galas-Filipowicz, Rakesh Popat, Karthik Ramasamy, Matthew Streetly, Ceri Bygrave, Reuben Benjamin, Ruth de Tute, Marquita Camilleri, Selina Chavda, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger Owen, Javier Herrero, Kwee Yong, and Michael Chapman

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

4. OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma

Author

Annie Cowan, Federico Ferrari, Samuel Freeman, Robert Redd, Habib El-Khoury, Jacqueline Perry, Vidhi Patel, Priya Kaur, Hadley Barr, David Lee, Elizabeth Lightbody, Katelyn Downey, David Argyelan, Foteini Theodorakakou, Louise Ainley, Selina Chavda, Omar Nadeem, Kwee Yong, Roman Hajek, Efstathios Kastritis, Catherine Marinac, Meletios A. Dimopoulos, Gad Getz, Lorenzo Trippa, and Irene Ghobrial

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

5. P-084: Bone marrow of patients post ASCT, but not chemotherapy consolidation, contains expanded T cell receptor clonotypes that are present at diagnosis: results from the Phase 2 CARDAMON study

Author

Kane Foster, Daria Galas-Filipowicz, Evie Fitzsimons, William Wilson, Lydia Lee, Suzanne Byrne, Karthik Ramasamy, Rakesh Popat, Michael Chapman, Matthew Streetly, Ceri Bygrave, Reuben Benjamin, Ruth de Tute, Marquita Camilleri, Selina Chavda, Elizabeth Philips, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger Owen, Benny Chain, and Kwee Yong

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

6. P-228: ASCT does not benefit patients who are MRD negative following induction therapy: updated results from the Phase 2 Cardamon study

Author

Kwee Yong, William Wilson, Ruth de Tute, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Jonathan Sive, Ceri Bygrave, Reuben Benjamin, Michael Chapman, Selina Chavda, Elizabeth Philips, Maria del Mar Cuadrado, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James Cavenagh, Laura Clifton-Hadley, Roger Owen, and Rakesh Popat

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

7. OAB-035: Characterising risk and biology Of smouldering myeloma for early detection of symptomatic myeloma: COSMOS, a prospective observational study in smouldering myeloma

Author

Louise Ainley, Elise Rees, Sayeh Foroughi, Gwennan Ward, Grant Vallance, Kane Foster, Selina Chavda, Firas Al-Kaisi, Ceri Bygrave, Hannah Hunter, Jindrinska Lindsay, Agapi Parcharidou, Lydia Lee, Karthik Ramasamy, and Kwee Yong

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

8. The Hands-on Guide to the Foundation Programme

Author

Anna Donald, Mike Stein, Ciaran Scott Hill, Selina Chavda, Anna Donald, Mike Stein, Ciaran Scott Hill, and Selina Chavda

Subjects
Clinical competence--Great Britain--Handbooks, manuals, etc, Clinical competence
Abstract

About to start the Foundation Programme?Making the transition from medical school to professional life? The Hands-on Guide to the Foundation Programme, Fifth Edition is a practical guide for medical students and foundation doctors, dealing with the many challenges of the programme. With hints, tips and realistic advice on various aspects of the course, from self-care to prescribing, this guide provides invaluable support, with up-to-date information on postgraduate training and recruitment, practical management skills and career pathways to help build confidence, enabling you to hit the ground running. This edition features newly expanded sections on emergencies, psychiatric evaluation, the Situational Judgement Test, and the common calls and conditions you will encounter on a daily basis. The Hands-on Guide to the Foundation Programme is a perfect companion to assist the junior doctor in preparing for the intellectual and emotional challenges of the foundation years.Take the stress out of the Foundation Programme with The Hands-on Guide!

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results